TOP STORIES

• BUSINESS Eisai Says 2 Trial Deaths Not Attributed to Lecanemab, No Change in Submission Plan
  December 1, 2022

• REGULATORY MOF Panel Presses for Full Annual Price Cuts, Rethink of COVID-Related Government Purchase
  November 30, 2022

• BUSINESS No Direct Causal Link between Lecanemab and Death in Clinical Trial: Eisai
  November 30, 2022

• REGULATORY Orlistat in Line for Approval as Japan’s 1st Nonprescription Obesity Drug after 4-Year Review
  November 29, 2022

• COMMENTARY Japan Should Hone Emergency Approval Scheme Based on Xocova Example
  November 28, 2022

• BUSINESS Shionogi Chief Defends Xocova Data, Eager to Prove Benefits in Clinical Settings
  November 25, 2022

• REGULATORY Japan Grants 1st Emergency Approval to Shionogi COVID Pill Xocova
  November 24, 2022

• COMMENTARY Pharma Industry Stays Pat on “No” to Off-Year Plan, Why Not Going for Trade-Off?
  November 22, 2022

• ACADEMIA Academic Societies Warn against Hoarding Meropenem as Supply Crunch Intensifies
  November 21, 2022

• BUSINESS Big 3 Generic Firms Struggle in H1; Nichi-Iko Logs Excess Debt as Profits Tank for Rivals
  November 18, 2022

• BUSINESS Merck R&D Chief Confident on Expanding Pipeline towards Keytruda Patent Cliff and Beyond
  November 17, 2022

• BUSINESS Top 4 Wholesalers on Recovery Trend, Operating Profit Up 69.1% in April-September
  November 16, 2022

• BUSINESS Nichi-Iko to Be Delisted, Seeks Turnaround under Medipal-JWP Joint Firm; President to Bow Out
  November 15, 2022

• REGULATORY Shionogi’s COVID Pill Up for 3rd Round of Discussion for Emergency Approval on Nov. 22
  November 15, 2022

• BUSINESS Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
  November 14, 2022

• REGULATORY Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
  November 14, 2022

• REGULATORY Zero Coefficient Rule Hits All 10 Premium-Granted Drugs Priced by Cost Formula in FY2022
  November 11, 2022

• REGULATORY Skyrizi Auto-Doser Peak Sales Put at 30-Plus Billion Yen, Mounjaro Not on Roster: November Listing
  November 10, 2022

• BUSINESS Lilly CEO Sees Donanemab’s Accelerated Nod in Coming Months, Japan Approval in 2024
  November 9, 2022

• REGULATORY MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
  November 8, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 62
• 63
• 64
• 65
• 66
• 67
• 68
• 69
• 70
• …
• Next ›
• 最終 »